Free Newsletter
USP to raise bar for drug transport
Drugmakers are about to be assigned greater responsibility for the in-transit portion of their finished products' supply chain expedition. A proposed revision to US Pharmacopeia section 1079, "Good Storage and Transportation Practices for Drug Products," maps the multi-handoff pathway from manufacturer to end user and reassesses it as a global, rather than regional, trek.
The draft revision, now out for comment, ups the ante to strategic planning from the tactical recommendations established in 2006, reports Pharmaceutical Commerce magazine. The update pushes manufacturers towards systems-level thinking: quality management systems for both storage and transportation, and environmental management requirements encompassing temperature monitoring devices and standard operating procedures. And it recommends a risk management system for assessing temperature excursions and other sources of product damage.
The public review runs through March. Completion is expected by end of year.
- here's the article
- view a background slide presentation
Related Articles:
Cold chain to rattle air transport
Product and European facility target cold chain
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
